WALTHAM, Massachusetts, Sept. 12 -- The New England Journal of Medicine, a peer-reviewed medical journal from the the Massachusetts Medical Society that says it delivers research and interactive clinical content to physicians, educators and the global medical community, published research articles on the following topics in its Sept. 8, 2022 edition: ORIGINAL ARTICLES: * Open-Source Automated Insulin Delivery in Type 1 Diabetes * Closed-Loop Therapy and Preservation of C-Peptide Secretion in  more

CALLAGHAN, Australia, Sept. 12 (TNSjou) -- The University of Newcastle issued the following news: * * * HMRI and University of Newcastle researchers have discovered that treating patients who have late-stage treatment resistant melanoma with a combination of two existing drugs significantly increases their survival times. * * * Led by Professor Nikola Bowden and Dr Andre van der Westhuizen from HMRI's Drug Repurposing and Medicines Research program, the project's findings have been published  more

HOUSTON, Texas, Sept. 12 -- The University of Texas's MD Anderson Cancer Center issued the following news release on Sept. 11, 2022: * * * MD Anderson presents patient-reported outcomes from DESTINY-Breast04 study * * * Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today  more

HOUSTON, Texas, Sept. 12 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release: * * * Response rates to anti-PD1 monotherapy are the highest reported for any solid tumor * * * In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3% of patients with stage II-IV cutaneous squamous cell carcinoma (CSCC) saw their tumors nearly or completely disappear when treated with immunotherapy befor  more